Vertebrogenic low back pain and basivertebral nerve ablation
Vertebrogenic pain is a proposed source of chronic axial low back pain arising from damaged vertebral endplates and transmitted through the basivertebral nerve. Intraosseous basivertebral nerve ablation is intended for a narrow, carefully selected population—not for every person with Modic changes or chronic back pain.
Vertebral endplates contain nociceptive fibres connected with the basivertebral nerve. Endplate damage can produce Type 1 or Type 2 Modic MRI changes. Trials of basivertebral nerve ablation generally enrolled adults with chronic axial low back pain lasting at least six months, failure of conservative care and Modic Type 1 or 2 changes from L3 to S1, while excluding major radiculopathy, severe stenosis, instability and several competing pain sources.
Assessment and differential diagnosis
Candidate selection must first exclude other dominant causes: nerve-root compression, symptomatic stenosis, severe facet pain, sacroiliac or hip disease, fracture, infection, malignancy, instability and persistent pain mechanisms that are unlikely to respond to an endplate-targeted procedure. MRI findings should match the vertebral levels and chronic axial pain pattern. The published trials used detailed exclusion criteria, so broad commercial expansion beyond those populations introduces uncertainty.
| Clinical pattern | Possible interpretation | Why it matters |
|---|---|---|
| Chronic axial low back pain with Modic 1 or 2 changes and failed conservative care | BVN ablation may be discussed | Published trials most closely resemble this population. |
| Dominant radicular leg pain from herniation | Treat the nerve-root condition | BVN ablation is not a discectomy or foraminal decompression. |
| Severe stenosis, instability or fracture | Different pathway required | The structural problem changes the treatment target. |
| Modic changes without a concordant clinical pattern | Do not assume vertebrogenic pain | MRI findings alone are insufficient. |
Treatment and decision-making
The procedure is performed under imaging guidance using an intraosseous approach to reach the basivertebral nerve within selected vertebral bodies. It is generally considered after an adequate trial of non-surgical care. Rehabilitation and activity progression remain relevant after the procedure. Risks include infection, bleeding, nerve injury, fracture, transient pain, anaesthesia-related complications and treatment failure. Access and reimbursement vary by jurisdiction.
How to interpret progress and avoid common mistakes
A credible plan should explain not only what treatment may be tried, but also how the diagnosis will be reconsidered if the expected response does not occur. Pain intensity can fluctuate for reasons that do not necessarily reflect tissue damage, while neurological or systemic deterioration can occur even when pain changes little. For that reason, progress should be judged with several measures rather than one daily pain score.
Establish a baseline
Record symptom distribution, aggravating activities, walking or sitting tolerance, sleep, medication use and the neurological findings relevant to this condition.
Choose a meaningful goal
Define a practical target such as walking farther, sleeping through the night, returning to work, tolerating sitting or recovering strength.
Use a planned review point
Decide in advance when the response will be reviewed rather than continuing indefinitely because a treatment package has not been completed.
Separate symptom relief from diagnosis
A temporary improvement after medication, manual care, injection or a device does not by itself prove that the proposed structure was the true pain source.
Watch the overall trajectory
Small day-to-day fluctuations are common. The more important question is whether function, neurological safety and participation are improving over time.
Escalate when the pattern changes
New weakness, systemic illness, vascular change, severe night pain or loss of bladder or bowel control requires a different pathway rather than more of the same treatment.
Assumptions that should be avoided
- Do not assume that every abnormal image is symptomatic.
- Do not assume that one negative test excludes the condition when clinical suspicion remains.
- Do not use treatment response as the only diagnostic test.
- Do not delay referral simply to finish a predetermined number of visits.
- Do not generalize results from a narrowly selected trial population to every person with a similar label.
- Do not interpret the absence of severe pain as proof that neurological or systemic risk is absent.
Shared decision-making is strongest when uncertainty is stated directly. A provider should be able to explain which findings support the working diagnosis, which competing diagnoses remain possible, what evidence applies to the proposed intervention, and what would trigger imaging, laboratory testing, specialist referral or a change of plan. When several conditions can produce similar symptoms, the safest approach is often staged: first exclude urgent disease, then identify the most likely mechanism, begin proportionate care and reassess against objective goals.
Questions before choosing care
What is the leading diagnosis?
Ask which findings support it and which alternatives remain.
What test would change care?
Avoid testing that cannot alter the next step.
What result matters?
Track function, neurological safety and meaningful activity.
When should the plan change?
Define referral, stopping and escalation criteria.
Relevant specialized resources
Some resources may share ownership or editorial direction; this relationship is disclosed and the links are included for contextual relevance.
Frequently asked questions
What is vertebrogenic pain?
A proposed axial pain mechanism arising from damaged vertebral endplates.
Are Modic changes required?
The major clinical trials generally required Type 1 or Type 2 changes.
Do Modic changes prove the pain source?
No.
Is BVN ablation the same as facet radiofrequency?
No. It targets an intraosseous nerve rather than medial branch nerves.
Does the procedure treat sciatica?
It does not directly decompress a nerve root.
How long have benefits lasted in studies?
Pooled prospective data report outcomes through about five years.
Can the nerve grow back?
Long-term biological behaviour is still studied; durable clinical outcomes have been reported.
Is the procedure reversible?
The nerve ablation itself is not reversed.
Is it covered in Canada?
Availability and reimbursement must be verified locally.
Does The Spine Page recommend the procedure?
No. It provides evidence and selection context.
Sources consulted
- Khalil et al. — Randomized trial of basivertebral nerve ablation
- Smuck et al. — Twelve-month randomized trial results
- Khalil et al. — Five-year pooled analysis
- North American Spine Society — Coverage recommendations
Last editorial review: July 2026. General educational information only.
Dr. Sylvain Desforges, B.Sc., D.O., N.D., osteopath — The Spine Page
Continue exploring spine health
Use the condition and treatment hubs to compare related guides.
The Spine Page — The best treatments for your spinal problems — www.thespinepage.com